HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Primary malignant mediastinal germ cell tumours: a literature review and a study of 18 cases.

Abstract
From 1957 to 1992, 18 cases of primary mediastinal germ cell tumours were referred to the Peter MacCallum Cancer Institute (PMCI). Six were seminomas, six were mixed germ cell tumours, two were embryonal cell carcinomas, three were teratocarcinomas and one was labelled an 'anaplastic germ cell tumour'. Two of the 18 patients were female. For seminomas, surgical (and in one case chemotherapeutic) debulking, followed by radiotherapy produced the best results. Mediastinal doses ranged from 30 to 40 Gy. Local control was achieved in those patients receiving mediastinal radiotherapy. Four patients currently survive disease-free. The non-seminomatous germ cell tumours showed a significantly poorer survival, and only two of 12 patients remain alive in remission at 110 and 130 months after diagnosis. Survival has been updated as of November 1997. Attention is focused on the anterior position of the primary germ cell tumours in the mediastinum. A review of the literature up to and including 1997 is presented.
AuthorsJ D Kiffer, T F Sandeman
JournalAustralasian radiology (Australas Radiol) Vol. 43 Issue 1 Pg. 58-68 (Feb 1999) ISSN: 0004-8461 [Print] Australia
PMID10901872 (Publication Type: Journal Article, Review)
Topics
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Dysgerminoma (mortality, pathology, therapy)
  • Female
  • Humans
  • Infant
  • Male
  • Mediastinal Neoplasms (mortality, pathology, therapy)
  • Middle Aged
  • Neoplasms, Germ Cell and Embryonal (mortality, pathology, therapy)
  • Survival Analysis
  • Teratoma (mortality, pathology, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: